Study on SX-682 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Abiraterone

Inclusion Criteria

• Must have signed a consent form approved by an ethics committee before starting the study.
• Diagnosed with metastatic castration-resistant prostate cancer (mCRPC) and have been treated with abiraterone and prednisone.
• Show signs of cancer progression, such as rising PSA levels or new or growing tumors.
• Have tumor tissue available for future studies.
• Have low testosterone levels or be on ongoing androgen deprivation therapy (ADT).
• Have a performance status score of 70 or higher, indicating the ability to care for oneself.
• Be 18 years or older.
• Have a life expectancy of at least 6 months.
• Have recovered from previous treatments to a certain level of health.
• Have adequate bone marrow, liver, and kidney function based on specific blood tests.
• Agree to use effective birth control during the study and for 90 days after the last dose if not surgically sterile or if partners are not postmenopausal.
• Willing to provide written consent and authorization for the release of personal health information.

Exclusion Criteria

• Have had certain cancer treatments recently, such as docetaxel, radium-223, or PSMA-Lu177-617.
• Have taken ketoconazole or other specific cancer drugs, or have had multiple chemotherapy regimens.
• Have liver metastases visible on imaging tests.
• Have had recent radiotherapy or major surgery.
• Have received a live vaccine recently.
• Are participating in another clinical trial or have used an investigational device recently.
• Have an immune deficiency or are on high-dose steroids or other immunosuppressive therapy.
• Have serious heart conditions or uncontrolled high blood pressure.
• Have a history of another cancer unless treated and cancer-free for 2 years.
• Have untreated brain metastases or certain brain conditions.
• Have active autoimmune diseases requiring treatment in the past 2 years.
• Have a history of lung inflammation requiring steroids.
• Have an active infection needing treatment.
• Have uncontrolled HIV, Hepatitis B, Hepatitis C, or TB infections.
• Have any condition that could interfere with the study or is not in the best interest of the participant.
• Have psychiatric or substance abuse issues affecting study participation.
• Have had an organ transplant.
• Are taking medications that affect the heart's rhythm or certain liver enzymes, unless essential for care.
• Have a heart condition affecting the QT interval or have had recent heart surgery or events.